Within the European community more than a million individuals develop cancer every year (Moller Jensen et al., 1990) . Of these cases, over 50% will be aged over 70 years and this proportion will gradually increase as a result of longevity since age is a major risk determinant for malignancy. Despite the frequency of cancer in the elderly, treatment has often been given on an ad hoc basis and very rarely have structured management schemes been tested in prospective randomised trials. Undertreatment of cancer has been rife, irrespective of tumour site and the discipline of the clinician looking after the patient. 
Within the European community more than a million individuals develop cancer every year (Moller Jensen et al., 1990) . Of these cases, over 50% will be aged over 70 years and this proportion will gradually increase as a result of longevity since age is a major risk determinant for malignancy. Despite the frequency of cancer in the elderly, treatment has often been given on an ad hoc basis and very rarely have structured management schemes been tested in prospective randomised trials. Undertreatment of cancer has been rife, irrespective of tumour site and the discipline of the clinician looking after the patient. (Herron et al., 1960) . Under these circumstances the operative mortality was 33%, and 62% of patients developed postoperative complications. Another example of the benefits of specialisation in surgery is the Mayo Clinic experience with radical pancreatectomy for carcinoma of the pancreas, (Spencer et al., 1990) . Of a series of 42 consecutive patients aged over 70 years subjected to either radical, total or distal pancreatectomy the operative mortality rate was 9%. Surgical complications occurred in 28% of cases and medical problems in 12%. It was concluded that aggressive surgery should not be avoided on grounds of age alone.
Radiotherapy
The treatment of many cancers has become multidisciplinary with optimal results being achieved where there is close cooperation between pathologist, surgeon, radiotherapist and medical oncologist. However, this approach may not be adopted in management of elderly patients. Chu et al. examined various aspects of the impact of age on treatment of cancer (Chu et al., 1987 (Fisher et al., 1985) . This was substantially reduced among those who were irradiated.
In a non-randomised study, Kantorowitz et al., reported that only 40% of patients aged over 60 years were referred for post-operative irradiation after wide local excision, (Kantorowitz et al., 1988) . Relapse of cancer within the breast occurred in 40% of those who were not irradiated, compared with only 6% of those given post-operative radiotherapy.
Chemotherapy
Several real and theoretical problems complicate the use of chemotherapy in elderly patients. Firstly, some will have undiagnosed pre-existing conditions leading to impairment of myocardial or pulmonary function. Others will be receiving a variety of drugs, and it has been suggested that interaction may occur in up to 50% of cases. (Brown et al., 1977) . Compliance with treatment may not occur in up to one third, and half may make errors in self-medication, (Schwartz et al., 1962) .
Both hepatic and renal function may be reduced as a result of age changes and there may be a loss of up to one third of the bone marrow stem cells thereby leading to potential toxicity (Ouslander, 1981) . Alteration in tissue cellularity and fatty replacement may act together with reduced excretion of drugs to amplify toxicity at target organs (Montamat, 1989) .
There are a variety of approaches to this problem of which the least effective may be to introduce empirical reductions in all the elderly irrespective of their functional capacity. Another approach is to tailor dose reduction to renal function when using cytotoxics excreted by this route. Gelman et al. proposed dose reduction of CMF for patients with advanced breast cancer in relation to creatinine clearance, (Gelman & Taylor, 1984) . This achieved a significant reduction in toxicity but with a concomitant loss of efficacy.
A more logical plan may be to study the pharmacokinetics of drug treatment in the elderly to attempt to achieve a similar target area under the time/concentration curve to that observed with younger patients (Monfardini, 1991 (Greenfield et al., 1987) . Notes were rated on a basis of diagnostic workshop, adequacy of staging, and appropriateness of treatment. In addition co-morbidity was graded. (Yancik et al., 1989) . Surgery was less likely to be performed in those aged over 85, and in this group was less likely to be extensive. When divided into stages and after adjusting for non-cancer deaths there was no difference in the survival of those with localised disease, irrespective of age.
The treatment of breast cancer has been both improved and complicated by the advent of tamoxifen, a non-toxic partial oestrogen antagonist. After being used extensively for the treatment of advanced breast cancer and also as an adjuvant after surgery for early disease, it was then used to treat operable disease in the elderly. In the study with the longest follow-up Horobin reported results on 113 patients aged over 70 years given tamoxifen 20 mg twice daily (Horobin et al., 1991) . Progression of disease was observed originally in 24 (21%). With a minimum follow-up of 5 years progression occurred in a further 37 (33%). There were 16 (14%) alive without relapse and 26 (23%) who died without progression. Thus overall, tamoxifen achieved long-term control in 42 (37%).
Various prospective randomised trials have been conducted to examine the role of tamoxifen in the elderly, and each had a different design, as shown in Table III (Gazet et al., 1988; Robertson et al., 1988; Bates et al., 1991) . With the exception of the St Georges trial, which compared sub-optimal surgery with tamoxifen, all the other studies have shown an increased risk of relapse in the breast of those given tamoxifen. The EORTC trials have not yet been analysed. A preliminary analysis has been conducted of the Guy's Hospital component of 10850. Of a total of 134 patients, 61 were treated by modified radical mastectomy and 73 by tumourectomy and tamoxifen. After a median follow-up of 6 years relapse free survival was 68% for the tamoxifen group and 80% for the mastectomy group. Overall survival of the two groups was similar (78% and 80%). Thus these studies suggest that tamoxifen alone may achieve long term control in less than 50% of patients, and this may increase to two thirds of those treated by tumourectomy and tamoxifen. There may be a subset who can be treated by tamoxifen without risk of relapse but such cases have not yet been identified. At present long-term follow-up is necessary which may be difficult for some patients. Although mastectomy achieves satisfactory long term control of local disease, this may be unacceptable to many. A different approach to this problem may be to use a combination of surgery and radiotherapy, but give the entire radiation treatment using an iridium or caesium implant, which would enable the entire treatment to be given over 5 days (Fentiman et al., 1991) .
This type of approach would be applicable to anyone fit enough for general anaesthesia. For the very frail, a hypofractioned treatment given on three occasions on an outpatient basis may be a more effective form of local control than tamoxifen alone. Such approaches warrant testing in clinical trials.
Conclusions
The attitudes of both patients and doctors have to be changed in relation to the management of cancer in the elderly. Entry criteria for clinical trials need to be broadened so that age alone is not a barrier. For those patients who are not entered into trials, their treatment should be the best available. Criteria for frailty need to be agreed and specific protocols designed for the improvement of treatment for such individuals. The elderly are an appropriate group to receive effective treatment and their inclusion in studies will increase the chances of improving the results of both local and systemic therapies.
